VimRx Pharmaceuticals Inc. of Stamford, Conn.,(NASDAQ:VMRX) said Thursday that the National Institute ofAllergy and Infectious Diseases is beginning Phase I clinicaltrials of VimRxyn hypericin in its AIDS clinical trial unit atNew York University Medical Center. In vitro studies ofhypericin, a plant derivative of St. John's wort, show it to beeffective in preventing the spread of HIV from infected cellsto uninfected cells.

(c) 1997 American Health Consultants. All rights reserved.